@article{5be9c36a250240508981b6250d53d2c1,
title = "Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review",
abstract = "Expansion of extracellular fluid volume is central to the pathophysiology of heart failure. Increased extracellular fluid leads to elevated intracardiac filling pressures, resulting in a constellation of signs and symptoms of heart failure referred to as congestion. Loop diuretics are one of the cornerstones of treatments for heart failure, but in contrast to other therapies, robust clinical trial evidence to guide the use of diuretics is sparse. A nuanced understanding of renal physiology and diuretic pharmacokinetics is essential for skillful use of diuretics in the management of heart failure in both the inpatient and outpatient settings. Diuretic resistance, defined as an inadequate quantity of natriuresis despite an adequate diuretic regimen, is a major clinical challenge that generally portends a poor prognosis. In this review, the authors discuss the fundamental mechanisms and physiological principles that underlie the use of diuretic therapy and the available data on the optimal use of diuretics.",
keywords = "congestion, diuretics, heart failure, pharmacology",
author = "Felker, {G. Michael} and Ellison, {David H.} and Wilfried Mullens and Cox, {Zachary L.} and Testani, {Jeffrey M.}",
note = "Funding Information: Dr. Felker has received research grants from the National Heart, Lung, and Blood Institute, American Heart Association, Amgen, Merck, Cytokinetics, and Roche Diagnostics; and has received consulting income from Novartis, Amgen, Bristol-Myers Squibb, Cytokinetics, Medtronic, Cardionomic, Relypsa, V-Wave, Myokardia, Innolife, EBR Systems, Arena, Abbott, Sphingotec, Roche Diagnostics, Alnylam, LivaNova, Windtree Therapeutics, Rocket Pharma, and SC Pharma. Dr. Cox has received research grants from Otsuka Pharmaceuticals. Dr. Testani has received grants from Sequana Medical, Bristol-Myers Squibb, 3ive Labs, Boehringer Ingelheim, Otsuka, Sanofi, FIRE1, and Abbott; has received consulting fees from Sequana Medical, AstraZeneca, Novartis, 3ive Labs, Boehringer Ingelheim, MagentaMed, Reprieve, Sanofi, FIRE1, and W.L. Gore; and has received personal fees from Cardionomic and Renalguard. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2020 American College of Cardiology Foundation",
year = "2020",
month = mar,
day = "17",
doi = "10.1016/j.jacc.2019.12.059",
language = "English (US)",
volume = "75",
pages = "1178--1195",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "10",
}